Developer docs
API playgroundTry for free, no card

Search company profiles

EMQN

Full company profile

uuid00083lo

Namestring
EMQN
Legal namestring
EMQN CIC
Websiteurl
emqn.org
Company typeenum
Private
Founded yearint
1997
Descriptiontext

EMQN CIC is a UK Community Interest Company serving the human molecular pathology and genomics testing market. It provides External Quality Assessment schemes, also referred to as proficiency tests, for hospital laboratories, private testing companies, point-of-care testing sites, academic medical centers, and other laboratories that need objective evidence of testing quality for accreditation, quality assurance, and clinical reporting reliability. Its portfolio spans more than 50 EQA schemes across genomic and inherited disorders, molecular pathology, NGS and Sanger sequencing, non-invasive prenatal testing, pharmacogenetics, pre-analytical processes, individual competence assessment, and point-of-care genetic testing.

The company's core product is an EQA process that tests the analytical workflow from sample through testing, interpretation, and final report. Technical components include patient-like cell-based swabs, Microbix-produced Quality Assessment Products formatted onto Copan FLOQSwabs, tumor profiling validation services for FFPE cancer tissues and cfDNA, and an in-development CRISPR-Cas9 engineered CYP2C19 cell-line reference material program with the University of Manchester. EMQN also relies on an expert peer assessor network, with at least two assessors per EQA, and publishes best-practice guidelines and educational content.

EMQN monetizes primarily through EQA scheme participation fees, while membership has been free since 2022. The model also includes sponsored schemes funded partly or fully by third parties such as pharmaceutical companies, replacement and extra sample charges, and device verification sample sales. Go-to-market is mainly direct and account-based through the eqa.emqn.org portal, supplemented by regional distributors and agents for markets including Bulgaria, Greece, Albania, China, Switzerland, Australia, Italy, Turkey, and EU-based logistics support.

Short descriptiontext

EMQN is a UK Community Interest Company providing External Quality Assessment schemes, reference materials, peer assessment, and best-practice guidance for hospital, private, academic, and point-of-care laboratories performing molecular pathology and genomic testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSalford, United Kingdom
HQ citystring
Salford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic quality assessment, molecular diagnostics EQA, proficiency testing services, external quality assessment, laboratory accreditation support
Industry3 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • Testing Laboratories and Services541380
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
External Quality Assessment Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1EQA Scheme Participation Fees
TypeSubscription Recurring
Description

Laboratories pay subscription/membership fees and scheme participation fees to access EQA schemes. Membership has been free since 2022, but scheme registration fees apply. Invoicing occurs annually in April after registration closes, with 30-day payment terms.

emqn.org
2Sponsored EQA Schemes
TypeSubscription Recurring
Description

Third-party organizations (e.g., pharmaceutical companies like MSD, AstraZeneca) sponsor some EQA schemes, covering part or all participation fees. Fully sponsored schemes show £0 fee; partially sponsored schemes show subsidized rates. Common for HRD, cfDNA, and other specialized schemes.

support.emqn.org
3Replacement and Extra Sample Fees
TypeOne Time License
Description

Additional charges for replacement samples due to technical errors or sample mix-ups, and extra materials for technologies requiring larger DNA volumes. Fees range from £70-£535 depending on scheme type and quantity.

support.emqn.org
4Device Verification Samples
TypeOne Time License
Description

Sale of device verification samples (DVS) to support POCT device implementation and verification, such as MT-RNR1 and CYP2C19 DVS packages.

support.emqn.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details5 tiers
1MT-RNR1 POCT EQA Scheme annual subscription
ModelSubscriptionBilling cadenceAnnual
Notes

£1300 per year. Includes three EQA samples bimonthly (18 samples per year) with results comparison to consensus.

support.emqn.org
2Replacement sample fees by scheme type
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Lung/Colorectal/Melanoma: £100 (1-4 samples), £175 (5-7), £250 (8-10/full set). Oncogene panel: £262. NGS schemes: £262. All other schemes: £70.

support.emqn.org
3Extra material fees for additional DNA volumes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Lung/Colorectal/Melanoma/Oncogene Panel: £262 (1 set), £315 (2 sets), £355 (3 sets). NGS Germline: £170 (1x extra), £205 (2x extra). NGS Somatic: £327 (1x), £370 (2x). NGS Somatic+germline: £490 (1x), £535 (2x).

support.emqn.org
4Fully sponsored schemes
ModelSubscriptionBilling cadenceAnnual
Notes

£0 GBP for fully sponsored schemes. Examples include HRD pilot (MSD sponsored) and cfDNA extraction EQA (AstraZeneca sponsored in 2025).

support.emqn.org
5Evolving economies discount program
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Significant reduction in EQA fees for laboratories in IMF-defined emerging/developing economies for 4 years. Laboratories must participate for 5 consecutive years and pay full fees thereafter.

support.emqn.org
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EMQN provides External Quality Assessment (EQA) schemes, also referred to as proficiency tests (PT), for human molecular pathology and genomics testing laboratories. Each scheme assesses the complete analytical process from sample through testing and interpretation to final report, evaluated by at least two expert peer assessors. The portfolio includes over 50 EQA schemes covering genomic inherited disorders, molecular pathology, sequencing (NGS and Sanger), non-invasive prenatal testing, pharmacogenetics, individual competence assessment, pre-analytical processes, and point-of-care testing (POCT), supplemented by best practice guidelines, managed POCT services, and educational resources.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • One in 500 persons carry the MT-RNR1 m.1555A>G variant that can lead to hearing loss upon aminoglycoside antibiotic exposure
+1 more record
Product overview1 text field

EMQN (European Molecular Genetics Quality Network) provides a comprehensive portfolio of External Quality Assessment (EQA) schemes for human molecular pathology and genomics testing. The core offering consists of over 50 accredited EQA schemes including Genomic & Inherited Disorders, Molecular Pathology, Sequencing (NGS and Sanger), Non-invasive Prenatal Testing, Pharmacogenetics, Individual Competence Assessment, Pre-analytical processes, and Point-of-Care Testing. The portfolio includes specialized POCT schemes for MT-RNR1 and CYP2C19 testing with device verification packages and managed services. Additional offerings include pilot schemes (HRD, Pan-Fusion), interlaboratory comparison programmes, educational webinars, and best practice guidelines. EMQN's schemes are designed to assess the complete analytical process from sample through testing and interpretation, with expert peer assessors evaluating laboratory performance.

Product and service8 records
1Genomic & Inherited Disorders EQA Scheme
CategoryEQA Scheme
Description

External Quality Assessment scheme for genetic testing and reporting of genomic and inherited disorders; assesses the full analytical process from sample through testing and interpretation to final report.

2Molecular Pathology EQA Scheme
CategoryEQA Scheme
Description

External Quality Assessment scheme covering molecular pathology testing; evaluates laboratory performance in analysing samples and interpreting results against mock clinical referral information.

3Sequencing (NGS and Sanger) EQA Scheme
CategoryEQA Scheme
Description

Technical EQA scheme for next-generation sequencing (NGS) and Sanger sequencing methodologies, assessing laboratory accuracy and performance.

4Non-invasive Prenatal Testing (NIPT) EQA Scheme
CategoryEQA Scheme
Description

External Quality Assessment scheme for non-invasive prenatal testing, evaluating laboratory capability in prenatal genetic analysis.

5Pharmacogenetics EQA Scheme
CategoryEQA Scheme
Description

External Quality Assessment scheme for pharmacogenetic testing, supporting accurate identification of genetic variants affecting drug metabolism.

6Individual Competence Assessment
CategoryEQA Scheme
Description

Scheme assessing individual competence of laboratory professionals in molecular diagnostics testing and interpretation.

7Pre-analytical EQA Scheme
CategoryEQA Scheme
Description

External Quality Assessment scheme for pre-analytical processes, evaluating sample handling and preparation procedures.

8MT-RNR1 Point-of-Care Testing EQA Scheme
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-04-10
Description

CADDA Knowledge Transfer Vouchers-funded collaboration for 'Engineered CYP2C19 Cell Lines for Point-of-Care Test Quality Assessment'. Using CRISPR-Cas9 genome editing to develop high-quality reference materials containing clinically important CYP2C19 variants for pharmacogenomic POCT validation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Second genetic-test EQA program collaboration for CYP2C19 POCT testing. Microbix QAPs support proficiency testing for sites detecting CYP2C19 variants affecting Clopidogrel metabolism. Participants receive three samples every two months (18 per year).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-10
Description

Microbix produces Quality Assessment Products (QAPs) formatted onto Copan FLOQSwabs for EMQN's genetic testing EQA programs, specifically MT-RNR1 POCT scheme. QAPs enable proficiency testing for acute care genetic testing. Sean Sales (EMQN Operations Director) and Cameron Groome (Microbix CEO) jointly announced the partnership.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-09-24
Description

Informed Genomics provides tumor profiling services to EMQN, including variant detection validations in FFPE cancer tissues and cfDNA analysis. This supports EMQN's quality assurance activities and assessment of clinical laboratories. Simon Patton (EMQN CEO) cited high standards alignment.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Ridacom is EMQN's trusted regional distributor for Bulgaria, Greece, and Albania. Provides full access to EMQN's genomics EQA schemes with local language support, regionally tailored marketing, and first-line technical support. Joint webinars, seminars, and tradeshows planned.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

EMQN contributed educational materials including a 20-minute lecture on EQA in Molecular Pathology, summary documents, academic paper lists, and multiple-choice questions to Oxford's MSc in Precision Medicine program (2025/2026). Invited by Helene Dreau, Principal Clinical Scientist.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

European Reference Network for rare genetic tumour risk syndromes endorsed EMQN's best practice guidelines for hereditary breast and ovarian cancer (HBOC). HBOC experts and MD patient representative reviewed guidelines and recommended them for ERN GENTURIS use.

Strategic tierSupportingTypeTechnology or Integration
Description

Copan supplies FLOQSwabs used in EMQN's QAP programs with Microbix for genetic testing EQA schemes (MT-RNR1, CYP2C19 POCT). Samples formatted onto FLOQSwabs enable participant processing similar to patient cheek/buccal swabs.

9Pharmaceutical Sponsors (MSD, AstraZeneca, others)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major pharmaceutical companies sponsor specific EQA schemes. MSD sponsors HRD pilot scheme. AstraZeneca sponsors cfDNA extraction EQA (2025). Sponsorship covers part or full scheme fees for participating laboratories.

support.emqn.org
10Other EQA Providers (GenQA, RfB, RCPAQAP, CSCQ, CF Network)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

EMQN collaborates with other EQA providers for certain schemes. Participant confidentiality is maintained during these collaborations. Information shared with RCPAQAP for Australasian labs, CSCQ for Swiss labs, NQAAP for UK labs.

emqn.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenQA is a UK-based EQA provider for genetics and genomics testing, offering proficiency testing schemes that directly overlap with EMQN's core molecular genetics and molecular pathology portfolio. EMQN's own data lists GenQA as a collaborating peer EQA provider.

TypeDirect peer
Description

UK NEQAS is one of the largest external quality assessment scheme providers globally, with molecular and genetics EQA offerings that compete with EMQN's scheme catalogue for hospital laboratory customers, particularly in the UK and Commonwealth markets.

3RCPAQAP
TypeDirect peer
Description

Royal College of Pathologists of Australasia Quality Assurance Programs provides EQA schemes across molecular genetics and pathology, explicitly named by EMQN as a collaborator for Australasian laboratories. Overlapping scheme portfolio makes it a direct peer in Asia-Pacific.

TypeDirect peer
Description

Labquality is a Finnish EQA scheme provider accredited to ISO 17043 with a broad molecular and clinical genetics portfolio, comparable in accreditation positioning and customer base to EMQN across European laboratories.

TypeDirect peer
Description

INSTAND is a German non-profit EQA provider offering molecular genetics and pathology proficiency testing schemes under ISO 17043 accreditation, directly competing with EMQN for European laboratory customers.

6CSCQ
TypeDirect peer
Description

Swiss Centre for Quality Control is a Switzerland-based EQA scheme provider named by EMQN as a collaborator for Swiss laboratories, with overlapping molecular and genetic testing EQA offerings.

TypeBroad incumbent
Description

CAP operates large-scale molecular pathology and genetics proficiency testing programmes globally. It is a broader incumbent whose portfolio includes but is not specialised to the genomic inherited disorders niche where EMQN focuses.

TypeBroad incumbent
Description

Bio-Rad provides quality controls, reference materials, and EQA-adjacent laboratory quality products to molecular diagnostics labs. While not a pure EQA scheme provider, it competes for laboratory quality budgets in the same space EMQN serves.

TypeOthers
Description

Microbix manufactures Quality Assessment Products used in EQA programmes and is a strategic supplier partner to EMQN for MT-RNR1 and CYP2C19 POCT schemes. It is an adjacent enabling partner in the EQA value chain rather than a direct competitor.

TypeOthers
Description

SensID is a reference material manufacturer whose cfDNA standards are used in EMQN's cfDNA extraction EQA sponsored by AstraZeneca. It is an ecosystem supplier enabling EMQN scheme content rather than a competing EQA provider.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EMQN

External Quality Assessment Servicesemqn.org

EMQN is a UK Community Interest Company providing External Quality Assessment schemes, reference materials, peer assessment, and best-practice guidance for hospital, private, academic, and point-of-care laboratories performing molecular pathology and genomic testing.

What EMQN does

EMQN CIC is a UK Community Interest Company serving the human molecular pathology and genomics testing market. It provides External Quality Assessment schemes, also referred to as proficiency tests, for hospital laboratories, private testing companies, point-of-care testing sites, academic medical centers, and other laboratories that need objective evidence of testing quality for accreditation, quality assurance, and clinical reporting reliability. Its portfolio spans more than 50 EQA schemes across genomic and inherited disorders, molecular pathology, NGS and Sanger sequencing, non-invasive prenatal testing, pharmacogenetics, pre-analytical processes, individual competence assessment, and point-of-care genetic testing.

The company's core product is an EQA process that tests the analytical workflow from sample through testing, interpretation, and final report. Technical components include patient-like cell-based swabs, Microbix-produced Quality Assessment Products formatted onto Copan FLOQSwabs, tumor profiling validation services for FFPE cancer tissues and cfDNA, and an in-development CRISPR-Cas9 engineered CYP2C19 cell-line reference material program with the University of Manchester. EMQN also relies on an expert peer assessor network, with at least two assessors per EQA, and publishes best-practice guidelines and educational content.

EMQN monetizes primarily through EQA scheme participation fees, while membership has been free since 2022. The model also includes sponsored schemes funded partly or fully by third parties such as pharmaceutical companies, replacement and extra sample charges, and device verification sample sales. Go-to-market is mainly direct and account-based through the eqa.emqn.org portal, supplemented by regional distributors and agents for markets including Bulgaria, Greece, Albania, China, Switzerland, Australia, Italy, Turkey, and EU-based logistics support.

EMQN firmographics

Firmographics
Name
EMQN
Legal name
EMQN CIC
Website
https://emqn.org
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
EMQN is a UK Community Interest Company providing External Quality Assessment schemes, reference materials, peer assessment, and best-practice guidance for hospital, private, academic, and point-of-care laboratories performing molecular pathology and genomic testing.
Ownership category
akta.pro rank

EMQN industry classification

Industry
Product category
External Quality Assessment Services
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Testing Laboratories and Services (541380)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Genomic quality assessment
  • Molecular diagnostics EQA
  • Proficiency testing services
  • External quality assessment
  • Laboratory accreditation support

Where EMQN is headquartered

Location

Headquarters

HQ city
Salford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

EMQN business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. EQA Scheme Participation Fees: Laboratories pay subscription/membership fees and scheme participation fees to access EQA schemes. Membership has been free since 2022, but scheme registration fees apply. Invoicing occurs annually in April after registration closes, with 30-day payment terms.
  2. Sponsored EQA Schemes: Third-party organizations (e.g., pharmaceutical companies like MSD, AstraZeneca) sponsor some EQA schemes, covering part or all participation fees. Fully sponsored schemes show £0 fee; partially sponsored schemes show subsidized rates. Common for HRD, cfDNA, and other specialized schemes.
  3. Replacement and Extra Sample Fees: Additional charges for replacement samples due to technical errors or sample mix-ups, and extra materials for technologies requiring larger DNA volumes. Fees range from £70-£535 depending on scheme type and quantity.
  4. Device Verification Samples: Sale of device verification samples (DVS) to support POCT device implementation and verification, such as MT-RNR1 and CYP2C19 DVS packages.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualMT-RNR1 POCT EQA Scheme annual subscription
Unit PricingPay-as-you-goReplacement sample fees by scheme type
Unit PricingPay-as-you-goExtra material fees for additional DNA volumes
SubscriptionAnnualFully sponsored schemes
SubscriptionMulti-year contractEvolving economies discount program

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

EMQN product offering

Product offering

Core offering

EMQN provides External Quality Assessment (EQA) schemes, also referred to as proficiency tests (PT), for human molecular pathology and genomics testing laboratories. Each scheme assesses the complete analytical process from sample through testing and interpretation to final report, evaluated by at least two expert peer assessors. The portfolio includes over 50 EQA schemes covering genomic inherited disorders, molecular pathology, sequencing (NGS and Sanger), non-invasive prenatal testing, pharmacogenetics, individual competence assessment, pre-analytical processes, and point-of-care testing (POCT), supplemented by best practice guidelines, managed POCT services, and educational resources.

Product overview

EMQN (European Molecular Genetics Quality Network) provides a comprehensive portfolio of External Quality Assessment (EQA) schemes for human molecular pathology and genomics testing. The core offering consists of over 50 accredited EQA schemes including Genomic & Inherited Disorders, Molecular Pathology, Sequencing (NGS and Sanger), Non-invasive Prenatal Testing, Pharmacogenetics, Individual Competence Assessment, Pre-analytical processes, and Point-of-Care Testing. The portfolio includes specialized POCT schemes for MT-RNR1 and CYP2C19 testing with device verification packages and managed services. Additional offerings include pilot schemes (HRD, Pan-Fusion), interlaboratory comparison programmes, educational webinars, and best practice guidelines. EMQN's schemes are designed to assess the complete analytical process from sample through testing and interpretation, with expert peer assessors evaluating laboratory performance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genomic & Inherited Disorders EQA Scheme External Quality Assessment scheme for genetic testing and reporting of genomic and inherited disorders; assesses the full analytical process from sample through testing and interpretation to final report.
  • Molecular Pathology EQA Scheme External Quality Assessment scheme covering molecular pathology testing; evaluates laboratory performance in analysing samples and interpreting results against mock clinical referral information.
  • Sequencing (NGS and Sanger) EQA Scheme Technical EQA scheme for next-generation sequencing (NGS) and Sanger sequencing methodologies, assessing laboratory accuracy and performance.
  • Non-invasive Prenatal Testing (NIPT) EQA Scheme External Quality Assessment scheme for non-invasive prenatal testing, evaluating laboratory capability in prenatal genetic analysis.
  • Pharmacogenetics EQA Scheme External Quality Assessment scheme for pharmacogenetic testing, supporting accurate identification of genetic variants affecting drug metabolism.
  • Individual Competence Assessment Scheme assessing individual competence of laboratory professionals in molecular diagnostics testing and interpretation.
  • Pre-analytical EQA Scheme External Quality Assessment scheme for pre-analytical processes, evaluating sample handling and preparation procedures.
  • MT-RNR1 Point-of-Care Testing EQA Scheme

Quantifiable outcome

  • One in 500 persons carry the MT-RNR1 m.1555A>G variant that can lead to hearing loss upon aminoglycoside antibiotic exposure
  • +1 more outcomes

Companies that use EMQN

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

EMQN technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EMQN partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered strategic, core, minor and supporting.

  • University of ManchesterstrategicStrategic or Co-development Partner · 10 April 2026CADDA Knowledge Transfer Vouchers-funded collaboration for 'Engineered CYP2C19 Cell Lines for Point-of-Care Test Quality Assessment'. Using CRISPR-Cas9 genome editing to develop high-quality reference materials containing clinically important CYP2C19 variants for pharmacogenomic POCT validation.
  • Microbix Biosystems Inc. (Second Program)coreStrategic or Co-development Partner · 23 September 2025Second genetic-test EQA program collaboration for CYP2C19 POCT testing. Microbix QAPs support proficiency testing for sites detecting CYP2C19 variants affecting Clopidogrel metabolism. Participants receive three samples every two months (18 per year).
  • Microbix Biosystems Inc.coreStrategic or Co-development Partner · 10 December 2024Microbix produces Quality Assessment Products (QAPs) formatted onto Copan FLOQSwabs for EMQN's genetic testing EQA programs, specifically MT-RNR1 POCT scheme. QAPs enable proficiency testing for acute care genetic testing. Sean Sales (EMQN Operations Director) and Cameron Groome (Microbix CEO) jointly announced the partnership.
  • Informed GenomicscoreTechnology or Integration · 24 September 2024Informed Genomics provides tumor profiling services to EMQN, including variant detection validations in FFPE cancer tissues and cfDNA analysis. This supports EMQN's quality assurance activities and assessment of clinical laboratories. Simon Patton (EMQN CEO) cited high standards alignment.
  • Ridacom LtdcoreChannel Partner/ Reseller/ DistributorRidacom is EMQN's trusted regional distributor for Bulgaria, Greece, and Albania. Provides full access to EMQN's genomics EQA schemes with local language support, regionally tailored marketing, and first-line technical support. Joint webinars, seminars, and tradeshows planned.
  • University of OxfordstrategicStrategic or Co-development PartnerEMQN contributed educational materials including a 20-minute lecture on EQA in Molecular Pathology, summary documents, academic paper lists, and multiple-choice questions to Oxford's MSc in Precision Medicine program (2025/2026). Invited by Helene Dreau, Principal Clinical Scientist.
  • ERN GENTURISminorStrategic or Co-development PartnerEuropean Reference Network for rare genetic tumour risk syndromes endorsed EMQN's best practice guidelines for hereditary breast and ovarian cancer (HBOC). HBOC experts and MD patient representative reviewed guidelines and recommended them for ERN GENTURIS use.
  • CopansupportingTechnology or IntegrationCopan supplies FLOQSwabs used in EMQN's QAP programs with Microbix for genetic testing EQA schemes (MT-RNR1, CYP2C19 POCT). Samples formatted onto FLOQSwabs enable participant processing similar to patient cheek/buccal swabs.
  • Pharmaceutical Sponsors (MSD, AstraZeneca, others)coreStrategic or Co-development PartnerMajor pharmaceutical companies sponsor specific EQA schemes. MSD sponsors HRD pilot scheme. AstraZeneca sponsors cfDNA extraction EQA (2025). Sponsorship covers part or full scheme fees for participating laboratories.
  • Other EQA Providers (GenQA, RfB, RCPAQAP, CSCQ, CF Network)supportingStrategic or Co-development PartnerEMQN collaborates with other EQA providers for certain schemes. Participant confidentiality is maintained during these collaborations. Information shared with RCPAQAP for Australasian labs, CSCQ for Swiss labs, NQAAP for UK labs.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

EMQN competitors and assessment

Company assessment

Direct peers

  • GenQA: GenQA is a UK-based EQA provider for genetics and genomics testing, offering proficiency testing schemes that directly overlap with EMQN's core molecular genetics and molecular pathology portfolio. EMQN's own data lists GenQA as a collaborating peer EQA provider.
  • UK NEQAS: UK NEQAS is one of the largest external quality assessment scheme providers globally, with molecular and genetics EQA offerings that compete with EMQN's scheme catalogue for hospital laboratory customers, particularly in the UK and Commonwealth markets.
  • RCPAQAP: Royal College of Pathologists of Australasia Quality Assurance Programs provides EQA schemes across molecular genetics and pathology, explicitly named by EMQN as a collaborator for Australasian laboratories. Overlapping scheme portfolio makes it a direct peer in Asia-Pacific.
  • Labquality: Labquality is a Finnish EQA scheme provider accredited to ISO 17043 with a broad molecular and clinical genetics portfolio, comparable in accreditation positioning and customer base to EMQN across European laboratories.
  • INSTAND e.V. INSTAND is a German non-profit EQA provider offering molecular genetics and pathology proficiency testing schemes under ISO 17043 accreditation, directly competing with EMQN for European laboratory customers.
  • CSCQ: Swiss Centre for Quality Control is a Switzerland-based EQA scheme provider named by EMQN as a collaborator for Swiss laboratories, with overlapping molecular and genetic testing EQA offerings.

Broad incumbents

  • College of American Pathologists (CAP): CAP operates large-scale molecular pathology and genetics proficiency testing programmes globally. It is a broader incumbent whose portfolio includes but is not specialised to the genomic inherited disorders niche where EMQN focuses.
  • Bio-Rad Laboratories: Bio-Rad provides quality controls, reference materials, and EQA-adjacent laboratory quality products to molecular diagnostics labs. While not a pure EQA scheme provider, it competes for laboratory quality budgets in the same space EMQN serves.

Others

  • Microbix Biosystems: Microbix manufactures Quality Assessment Products used in EQA programmes and is a strategic supplier partner to EMQN for MT-RNR1 and CYP2C19 POCT schemes. It is an adjacent enabling partner in the EQA value chain rather than a direct competitor.
  • SensID: SensID is a reference material manufacturer whose cfDNA standards are used in EMQN's cfDNA extraction EQA sponsored by AstraZeneca. It is an ecosystem supplier enabling EMQN scheme content rather than a competing EQA provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights3 records

Customer concentration

EMQN social profiles

Digital presence

EMQN compliance and trust

Trust signal

Compliance3 records

EMQN financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EMQN leadership team

Management profile

Number of profiles

Profiles4 records

EMQN funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EMQN M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMQN

What does EMQN do?

EMQN provides External Quality Assessment (EQA) schemes, also referred to as proficiency tests (PT), for human molecular pathology and genomics testing laboratories. Each scheme assesses the complete analytical process from sample through testing and interpretation to final report, evaluated by at least two expert peer assessors. The portfolio includes over 50 EQA schemes covering genomic inherited disorders, molecular pathology, sequencing (NGS and Sanger), non-invasive prenatal testing, pharmacogenetics, individual competence assessment, pre-analytical processes, and point-of-care testing (POCT), supplemented by best practice guidelines, managed POCT services, and educational resources.

Is EMQN a public or private company?

EMQN is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was EMQN founded?

EMQN was founded in 1997. It employs 11 to 50 people.

Where is EMQN based?

EMQN is headquartered in Salford, United Kingdom, in the Europe region.

How does EMQN make money?

Four revenue lines are on record. EQA Scheme Participation Fees are the primary driver. The others are sponsored EQA Schemes, replacement and Extra Sample Fees and device Verification Samples.

Who are EMQN's main competitors?

Direct peers on record are GenQA, UK NEQAS, RCPAQAP, Labquality, INSTAND e.V. and CSCQ. Broad incumbents are College of American Pathologists (CAP) and Bio-Rad Laboratories. Others are Microbix Biosystems and SensID.

Does EMQN have an API?

No public API is recorded for EMQN.

What industry is EMQN in?

EMQN's product category is External Quality Assessment Services. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLACAOAA, Electronic Data Capture (EDC) Platforms. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals